In line with our long-term goal to use TIL-PDX mice to develop effective primary combination immunotherapies, we examined if the addition of IL-15 stimulation to PD-1 blockade augments the antitumor response of tumor-exhausted CTLs and NK cells in our TIL-PDX-LUAD model. This evidence concerns the gene IL15 and neoplasm.